Skip to content

Pfizer’s African Partner Produces First Doses of Covid Shots

  • Biovac has capacity to fill, package 100 million doses a year
  • Cape Town-based company expects expansion financing in 2023
A technician at the Biovac Institute facility, in Cape Town, South Africa.

A technician at the Biovac Institute facility, in Cape Town, South Africa.

Photographer: Dwayne Senior/Bloomberg
Updated on

The Biovac Institute, a partly state-owned vaccine producer in South Africa, has produced its first batch of Covid-19 vaccines as part of an arrangement under which it aims to fill and package as many as 100 million doses a year of Pfizer Inc. and BioNtech SE’s inoculation. 

The doses, produced last week, are the first Pfizer shots for the disease to be made in Africa and will be evaluated by the South African Health Regulatory Products Authority before subsequent batches are planned for commercial sale next year, said Morena Makhoana, the chief executive officer of Biovac.